Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
14.99
+0.88 (6.24%)
At close: Dec 20, 2024, 4:00 PM
15.11
+0.12 (0.80%)
After-hours: Dec 20, 2024, 5:39 PM EST
Arcutis Biotherapeutics Revenue
Arcutis Biotherapeutics had revenue of $44.76M in the quarter ending September 30, 2024, with 17.44% growth. This brings the company's revenue in the last twelve months to $138.71M, up 182.84% year-over-year. In the year 2023, Arcutis Biotherapeutics had annual revenue of $59.61M with 1,517.09% growth.
Revenue (ttm)
$138.71M
Revenue Growth
+182.84%
P/S Ratio
12.20
Revenue / Employee
$468,608
Employees
296
Market Cap
1.75B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Fortrea Holdings | 2.98B |
Teladoc Health | 2.59B |
Clover Health Investments | 2.12B |
Integra LifeSciences Holdings | 1.56B |
10x Genomics | 629.74M |
BioCryst Pharmaceuticals | 412.58M |
Dynavax Technologies | 260.81M |
RxSight | 128.29M |
ARQT News
- 14 days ago - Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Arcutis Biotherapeutics: +200% On ZORYVE Approval, But When Is The Next Leg Up? - Seeking Alpha
- 6 weeks ago - Arcutis Biotherapeutics, Inc. (ARQT) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference - GlobeNewsWire
- 2 months ago - Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q4 - Benzinga
- 2 months ago - Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older - GlobeNewsWire
- 3 months ago - New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types - GlobeNewsWire